Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

Xianming Deng; Jonathan M. Elkins; Jinwei Zhang; Qingkai Yang; Tatiana Erazo; Nestor Gomez; Hwan Geun Choi; Jinhua Wang; Nicolas Dzamko; Jiing-Dwan Lee; Taebo Sim; NamDoo Kim; Dario R. Alessi; Jose M. Lizcano; Stefan Knapp; Nathanael S. Gray

doi:10.1016/j.ejmech.2013.10.052

Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

Xianming Deng
, Jonathan M. Elkins
, Jinwei Zhang
, Qingkai Yang
, Tatiana Erazo
, Nestor Gomez
, Hwan Geun Choi
, Jinhua Wang
, Nicolas Dzamko
, Jiing-Dwan Lee
, Taebo Sim
, NamDoo Kim
, Dario R. Alessi
, Jose M. Lizcano
, Stefan Knapp
, Nathanael S. Gray

Research output: Contribution to journal › Article › peer-review

42 Citations (Scopus)

Abstract

The benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-one core was discovered as a novel ERK5 (also known as MAPK7 and BMK1) inhibitor scaffold, previously. Further structure-activity relationship studies of this scaffold led to the discovery of ERK5-IN-1 (26) as the most selective and potent ERK5 inhibitor reported to date. 26 potently inhibits ERK5 biochemically with an IC of 0.162 ± 0.006 µM and in cells with a cellular EC for inhibiting epidermal growth factor induced ERK5 autophosphorylation of 0.09 ± 0.03 µM. Furthermore, 26 displays excellent selectivity over other kinases with a KINOMEscan selectivity score (S) of 0.007, and exhibits exceptional bioavailability (F%) of 90% in mice. 26 will serve as a valuable tool compound to investigate the ERK5 signaling pathway and as a starting point for developing an ERK5 directed therapeutic agent.

Original language	English
Pages (from-to)	758-767
Number of pages	10
Journal	European Journal of Medicinal Chemistry
Volume	70
DOIs	https://doi.org/10.1016/j.ejmech.2013.10.052
Publication status	Published - Dec 2013

Keywords

Azepines
Cells, Cultured
Dose-Response Relationship, Drug
Enzyme Activation
HEK293 Cells
HeLa Cells
Humans
Mitogen-Activated Protein Kinase 7
Models, Molecular
Molecular Structure
Protein Kinase Inhibitors
Protein-Serine-Threonine Kinases
Pyrimidines
Structure-Activity Relationship

Access to Document

10.1016/j.ejmech.2013.10.052

Cite this

Deng, X., Elkins, J. M., Zhang, J., Yang, Q., Erazo, T., Gomez, N., Choi, H. G., Wang, J., Dzamko, N., Lee, J.-D., Sim, T., Kim, N., Alessi, D. R., Lizcano, J. M., Knapp, S., & Gray, N. S. (2013). Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. European Journal of Medicinal Chemistry, 70, 758-767. https://doi.org/10.1016/j.ejmech.2013.10.052

@article{91d20ac1ed574e80b62036751d4507ce,

title = "Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones",

abstract = "The benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-one core was discovered as a novel ERK5 (also known as MAPK7 and BMK1) inhibitor scaffold, previously. Further structure-activity relationship studies of this scaffold led to the discovery of ERK5-IN-1 (26) as the most selective and potent ERK5 inhibitor reported to date. 26 potently inhibits ERK5 biochemically with an IC of 0.162 ± 0.006 µM and in cells with a cellular EC for inhibiting epidermal growth factor induced ERK5 autophosphorylation of 0.09 ± 0.03 µM. Furthermore, 26 displays excellent selectivity over other kinases with a KINOMEscan selectivity score (S) of 0.007, and exhibits exceptional bioavailability (F\%) of 90\% in mice. 26 will serve as a valuable tool compound to investigate the ERK5 signaling pathway and as a starting point for developing an ERK5 directed therapeutic agent.",

keywords = "Azepines, Cells, Cultured, Dose-Response Relationship, Drug, Enzyme Activation, HEK293 Cells, HeLa Cells, Humans, Mitogen-Activated Protein Kinase 7, Models, Molecular, Molecular Structure, Protein Kinase Inhibitors, Protein-Serine-Threonine Kinases, Pyrimidines, Structure-Activity Relationship",

author = "Xianming Deng and Elkins, \{Jonathan M.\} and Jinwei Zhang and Qingkai Yang and Tatiana Erazo and Nestor Gomez and Choi, \{Hwan Geun\} and Jinhua Wang and Nicolas Dzamko and Jiing-Dwan Lee and Taebo Sim and NamDoo Kim and Alessi, \{Dario R.\} and Lizcano, \{Jose M.\} and Stefan Knapp and Gray, \{Nathanael S.\}",

year = "2013",

month = dec,

doi = "10.1016/j.ejmech.2013.10.052",

language = "English",

volume = "70",

pages = "758--767",

journal = "European Journal of Medicinal Chemistry",

issn = "0223-5234",

publisher = "Elsevier",

}

Deng, X, Elkins, JM, Zhang, J, Yang, Q, Erazo, T, Gomez, N, Choi, HG, Wang, J, Dzamko, N, Lee, J-D, Sim, T, Kim, N, Alessi, DR, Lizcano, JM, Knapp, S & Gray, NS 2013, 'Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones', European Journal of Medicinal Chemistry, vol. 70, pp. 758-767. https://doi.org/10.1016/j.ejmech.2013.10.052

TY - JOUR

T1 - Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

AU - Deng, Xianming

AU - Elkins, Jonathan M.

AU - Zhang, Jinwei

AU - Yang, Qingkai

AU - Erazo, Tatiana

AU - Gomez, Nestor

AU - Choi, Hwan Geun

AU - Wang, Jinhua

AU - Dzamko, Nicolas

AU - Lee, Jiing-Dwan

AU - Sim, Taebo

AU - Kim, NamDoo

AU - Alessi, Dario R.

AU - Lizcano, Jose M.

AU - Knapp, Stefan

AU - Gray, Nathanael S.

PY - 2013/12

Y1 - 2013/12

N2 - The benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-one core was discovered as a novel ERK5 (also known as MAPK7 and BMK1) inhibitor scaffold, previously. Further structure-activity relationship studies of this scaffold led to the discovery of ERK5-IN-1 (26) as the most selective and potent ERK5 inhibitor reported to date. 26 potently inhibits ERK5 biochemically with an IC of 0.162 ± 0.006 µM and in cells with a cellular EC for inhibiting epidermal growth factor induced ERK5 autophosphorylation of 0.09 ± 0.03 µM. Furthermore, 26 displays excellent selectivity over other kinases with a KINOMEscan selectivity score (S) of 0.007, and exhibits exceptional bioavailability (F%) of 90% in mice. 26 will serve as a valuable tool compound to investigate the ERK5 signaling pathway and as a starting point for developing an ERK5 directed therapeutic agent.

AB - The benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-one core was discovered as a novel ERK5 (also known as MAPK7 and BMK1) inhibitor scaffold, previously. Further structure-activity relationship studies of this scaffold led to the discovery of ERK5-IN-1 (26) as the most selective and potent ERK5 inhibitor reported to date. 26 potently inhibits ERK5 biochemically with an IC of 0.162 ± 0.006 µM and in cells with a cellular EC for inhibiting epidermal growth factor induced ERK5 autophosphorylation of 0.09 ± 0.03 µM. Furthermore, 26 displays excellent selectivity over other kinases with a KINOMEscan selectivity score (S) of 0.007, and exhibits exceptional bioavailability (F%) of 90% in mice. 26 will serve as a valuable tool compound to investigate the ERK5 signaling pathway and as a starting point for developing an ERK5 directed therapeutic agent.

KW - Azepines

KW - Cells, Cultured

KW - Dose-Response Relationship, Drug

KW - Enzyme Activation

KW - HEK293 Cells

KW - HeLa Cells

KW - Humans

KW - Mitogen-Activated Protein Kinase 7

KW - Models, Molecular

KW - Molecular Structure

KW - Protein Kinase Inhibitors

KW - Protein-Serine-Threonine Kinases

KW - Pyrimidines

KW - Structure-Activity Relationship

UR - https://www.scopus.com/pages/publications/84887384933

U2 - 10.1016/j.ejmech.2013.10.052

DO - 10.1016/j.ejmech.2013.10.052

M3 - Article

C2 - 24239623

AN - SCOPUS:84887384933

SN - 0223-5234

VL - 70

SP - 758

EP - 767

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

ER -

Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

A Systematic Investigation into the Pathogenesis and Course of Parkinson's Syndrome (Wellcome Trust and MRC Neurodegenerative Diseases Initiative) (Joint with University College London)

Cite this

Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Projects

A Systematic Investigation into the Pathogenesis and Course of Parkinson's Syndrome (Wellcome Trust and MRC Neurodegenerative Diseases Initiative) (Joint with University College London)

Cite this